Connie J Turner

Title: The Innovative Contributions of Connie J. Turner

Introduction

Connie J. Turner is a notable inventor based in Edmonton, Canada. She has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies for cancer detection and treatment. Her work has implications for improving diagnostic techniques and therapeutic strategies in oncology.

Latest Patents

Connie J. Turner holds a patent for "Carcinoma-marking monoclonal antibodies elicited with synthetic." This patent describes monoclonal antibodies produced after immunization with a synthetic antigen that is useful as carcinoma markers. The antibodies are tagged with radiometals or radiohalogens, making them effective as radioimmunoimaging agents. The radiolabeled monoclonal antibody 155H.7, elicited by this antigen, has shown the ability to rapidly localize and persist in tumor tissues, demonstrating its utility as a tumor imaging agent. She has 1 patent to her name.

Career Highlights

Connie has worked at Biomira, Inc., where she has been involved in groundbreaking research and development projects. Her innovative approach to cancer diagnostics has positioned her as a key figure in her field.

Collaborations

Throughout her career, Connie has collaborated with esteemed colleagues, including Bryan M. Longenecker and David J. Willans. These partnerships have enhanced her research and contributed to the advancement of cancer detection technologies.

Conclusion

Connie J. Turner is a pioneering inventor whose work in monoclonal antibodies has the potential to transform cancer diagnostics. Her contributions continue to influence the field and inspire future innovations.